Chemotherapy News and Research

Latest Chemotherapy News and Research

Nearly 50% of essential services provided for cancer treatment not reimbursed by Medicare

A comprehensive study of the components of the delivery of modern-day cancer care in community oncology practices revealed that Medicare covers only 56% of the actual costs of administering chemotherapy and providing related infusion room services to seniors with cancer. The remaining costs -- for essential services provided such as treatment planning, care coordination, and follow-up care planning -- are not reimbursed by Medicare, causing many oncology practices to struggle to continue to provide care under the Medicare program.

5 Feb 2010

Oxford Finance Corporation announces $25M credit facility to EUSA Pharma

Oxford Finance Corporation today announced that it is the agent and primary lender for a $25 million credit facility provided to EUSA Pharma. MidCap Financial and Silicon Valley Bank are co-lenders in the transaction.

5 Feb 2010

ARUP Laboratories adds three downstream cost calculators to its Suite of Utilization Management Services

ARUP Laboratories announced the release of three groundbreaking tools, downstream cost calculators, to its Suite of Utilization Management Services.

5 Feb 2010

Progenics Pharmaceuticals to present preclinical data of multiplex PI3K inhibitors

Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on a series of novel compounds that simultaneously blocked two critical pathways involved in the growth and survival of cancer cells.

4 Feb 2010

Wolters Kluwer Health relaunches flagship drug information reference as Facts & Comparisons eAnswers

Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that it has relaunched its flagship drug information reference as Facts & Comparisons® eAnswers.

4 Feb 2010

ASTRO leads the way to help physicians improve safety and reduce medical errors

The American Society for Radiation Oncology has committed to a six-point patient protection plan that will improve safety and quality and reduce the chances of medical errors, ASTRO Board Chairman Tim R. Williams, M.D., said today.

4 Feb 2010

Cancer Research UK opens Cambridge Cancer Centre

The launch of a centre today (Wednesday) puts Cambridge at the forefront of cancer research, bringing benefits to patients in the South East.

4 Feb 2010

Brentuximab vedotin-chemotherapy combination clinical trial for Hodgkin lymphoma announced

Seattle Genetics, Inc. and Millennium Pharmaceuticals, Inc.: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin (SGN-35) in combination with chemotherapy for the treatment of newly diagnosed Hodgkin lymphoma patients. Brentuximab vedotin is an antibody-drug conjugate (ADC) that is also in single-agent clinical trials, including a pivotal trial for relapsed and refractory Hodgkin lymphoma and a phase II trial for systemic anaplastic large cell lymphoma.

4 Feb 2010

Keryx Biopharmaceuticals reaches agreement with FDA on SPA for Phase 3 trial of KRX-0401

Keryx Biopharmaceuticals, Inc. announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathway inhibitor, KRX-0401 (perifosine), in patients with refractory metastatic colorectal cancer.

3 Feb 2010

News article on the evolving role of hyperthermia in cancer therapy

BSD Medical Corp. reports publication of a news article by the Journal of the National Cancer Institute on the evolving role of hyperthermia in cancer therapy titled, “International Study of Hyperthermia Spurs Hope in U.S.” (J. Natl. Cancer Inst. 2010 102: 79-81; doi:10.1093/jnci/djp530).

3 Feb 2010

Dayton Physicians select IntrinsiQ’s chemotherapy management system for improving patient care

Dayton Physicians LLC, one of Ohio’s leading multi-specialty cancer treatment centers, has selected IntrinsiQ’s IntelliDose® clinical software to manage complex chemotherapy treatment, safely and efficiently.

3 Feb 2010

FDA accepts Teva Pharmaceutical Industries' BLA for XM02 G-CSF

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing Teva’s Biologics License Application (BLA) for XM02, a granulocyte colony-stimulating factor (G-CSF) for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer.

2 Feb 2010

Cytheris broadens patent protection for recombinant human interleukin-7

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Glycosylated IL-7, Preparation and Uses", US Patent Application Number 11/996,176. The Notice of Allowance is the USPTO’s official communication that the Company’s application has successfully completed examination and that a patent will be issued.

2 Feb 2010

Abbott signs licensing agreement with Pierre Fabre SA to develop and commercialize cancer antibody h224G11

Abbott announced today an exclusive worldwide licensing agreement with Pierre Fabre SA to develop and commercialize h224G11, a pre-clinical monoclonal antibody identified at the Centre d'Immunologie Pierre Fabre (CIPF) in France and targeting the cMet receptor for the treatment of cancer.

1 Feb 2010

Belfast scientists identify gene that can help predict tamoxifen treatment failure

Scientists in Belfast have identified a gene which could predict whether women with breast cancer will respond to treatment with tamoxifen, according to findings published today in Cancer Research.

1 Feb 2010

FDA approves new drug combination for hormone positive and HER2-positive advanced breast cancer

The U.S. Food and Drug Administration today approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated.

30 Jan 2010

Salient Pharmaceuticals receives TETF commercialization award for CASAD therapy commercialization

Houston Technology Center (HTC), announced today that client company Salient Pharmaceuticals received a $2 million commercialization award from the Texas Emerging Technology Fund (TETF) for the commercialization of their CASAD therapy, an all natural product used to prevent and treat some cancer therapy-induced side effects.

29 Jan 2010

FDA grants accelerated approval for GlaxoSmithKline's TYKERB

GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for a new combination regimen using TYKERB® (lapatinib) as a first-line, all-oral treatment for women with metastatic breast cancer.

29 Jan 2010

Global market for oncology drugs is forecast to reach $80 billion by 2050

New Medicine's Oncology KnowledgeBASE (nm/OK) residing at http://nmok.net became available on the Internet 10 years ago and, since then, the oncology field has evolved into one of the most challenging, complex and promising drug development sectors, both in terms of its potential contribution to medicine and to its market opportunities.

29 Jan 2010

Study sheds light on pancreatic cancer development and new potential drug targets

Researchers at the Moores Cancer Center at the University of California, San Diego, have found one reason that pancreatic cancer tumors are so difficult to treat with drugs. They have shown how a molecular switch steps up pancreatic cancer cell survival as well as resistance to a standard chemotherapy drug, and have identified alternate routes cancer cells take to avoid the effects of the therapy.

29 Jan 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

Nearly 50% of essential services provided for cancer treatment not reimbursed by Medicare

Oxford Finance Corporation announces $25M credit facility to EUSA Pharma

ARUP Laboratories adds three downstream cost calculators to its Suite of Utilization Management Services

Progenics Pharmaceuticals to present preclinical data of multiplex PI3K inhibitors

Wolters Kluwer Health relaunches flagship drug information reference as Facts & Comparisons eAnswers

ASTRO leads the way to help physicians improve safety and reduce medical errors

Cancer Research UK opens Cambridge Cancer Centre

Brentuximab vedotin-chemotherapy combination clinical trial for Hodgkin lymphoma announced

Keryx Biopharmaceuticals reaches agreement with FDA on SPA for Phase 3 trial of KRX-0401

News article on the evolving role of hyperthermia in cancer therapy

Dayton Physicians select IntrinsiQ’s chemotherapy management system for improving patient care

FDA accepts Teva Pharmaceutical Industries' BLA for XM02 G-CSF

Cytheris broadens patent protection for recombinant human interleukin-7

Abbott signs licensing agreement with Pierre Fabre SA to develop and commercialize cancer antibody h224G11

Belfast scientists identify gene that can help predict tamoxifen treatment failure

FDA approves new drug combination for hormone positive and HER2-positive advanced breast cancer

Salient Pharmaceuticals receives TETF commercialization award for CASAD therapy commercialization

FDA grants accelerated approval for GlaxoSmithKline's TYKERB

Global market for oncology drugs is forecast to reach $80 billion by 2050

Study sheds light on pancreatic cancer development and new potential drug targets

Cancer Research - Second Edition eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in